{"id":1014767,"date":"2026-10-28T16:07:03","date_gmt":"2026-10-28T20:07:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/"},"modified":"2026-10-28T16:07:03","modified_gmt":"2026-10-28T20:07:03","slug":"ars-pharma-to-report-third-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/","title":{"rendered":"ARS Pharma to Report Third Quarter 2026 Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN DIEGO, Oct.  28, 2026  (GLOBE NEWSWIRE) &#8212; ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT \/ 4:30 p.m. ET to review its third quarter 2026 financial results.<\/p>\n<p>Dial-in information for conference participants may be obtained by\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nP7Sepj3g6V1vbVcvizFL0EiYiKGwEY_auMiGm7USzyksInU-5Rg652tUwNO-r68ywgtQ3XcNGn8ZHD7kozZnAEuDWpzr0gv00whk8aNMDxKMIFX12KwfqI_V4FELRafhK2eNdWl2ZTSG41iB-_ttRXBd0MLEca6mbVw2FUNH844L-HX2V2R0kfCMYdMZSU2\" rel=\"nofollow\" target=\"_blank\">registering for the event<\/a>. To access the webcast and slides, please visit the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-K1ZjGiNmggCu6Qm3gNLArpeglxsIJqOUxdjSHtU7PiwsxauHobfH9DxkiHd8sGHknTL5sl_A2EGkE9Bz5KomQLsfEg8m5mwSTAG6Df4snw2BxyXiOzPVe9SaF8j_lBH_d_2cgzZ245CAdrizJIqEBS4TYe5hOpqgvWT988qfLvYBb4l1tOFoPho8VTvrWlujPW2_sMRUDsfzD7fEaGmKPTGxomh65BI9bzHcejO5UmapW3_ay6iph1fmC3v5ORVDzFkIQFVMv92siAfQkilCviiPaxuTrUgkJLbawCdPTjS7gYyzBDr0mWhXQYI1H01RxHqhHDG1STc1o5peyFE4A==\" rel=\"nofollow\" target=\"_blank\">Events &amp; Presentations<\/a>\u00a0page in the Investors &amp; Media section of the Company\u2019s\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rMIDHejUvy22is4hrcUGtPJrsId1bKHXfg83CIPemVj21MG8J9alnzfcSwtKxB19LifBq4sSpg84jaX0ejdShN1HEnt1wpiovg7UuNZmJMVC3s4PvWyPAutvqpBwbGOQ-hd0FuD4PC27zdpuicRVscLwwQwdOq32avAJMGdIzECUAktCKoUsPmGYtQPF4JKosIwYQSTL9AGn1JI9vJwABuy5FQP-1hjTvZtn3GAoQYw=\" rel=\"nofollow\" target=\"_blank\">website<\/a>. A replay of the webcast will be available for 30 days following the event.<\/p>\n<p>\n        <strong>About ARS Pharmaceuticals, Inc.<\/strong><br \/>\n        <br \/>ARS Pharma is a biopharmaceutical company developing and commercializing treatments that help at-risk patients and their caregivers treat and prevent severe allergic reactions. The company is commercializing <em>neffy<\/em>\u00ae (epinephrine nasal spray), the only needle-free epinephrine approved by the U.S. Food &amp; Drug Administration and European Medicines Agency, for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. (15kg) or more. The product is marketed as <em>EURneffy<\/em>\u00ae in the European Union and as \u4f18\u654f\u901f\u00ae in China. Leveraging its intranasal technology, ARS Pharma is also developing ARS-2, currently in a Phase 2b clinical trial, as a potential first treatment for acute flares of chronic spontaneous urticaria (CSU). For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m94ptmCzyHNERmkwLMl64XRPCtsrVrjN0Gp1w7w9ua5DHDgSB9mnGyKdXIFUda0n0s6X-D8AMyGu0CXw0z8iiqrs6vUajfHWPOOPJJT9c4Iu-Z4nLPhZVLjcdmBq5g1RbdbFUOReh6BOaazV3oNxrD5kIBU36F6YFXfWz5icEAB3qM-GucO7k_amPYwU2ZZRKSCWhEwYfxbVcmYuIaNMdhc0GmXSEDErH1kPSLqyIIc-PDiLFF-EqajIMr5U-HvH3MNAvYRCeEvGQaaZmcF2-A==\" rel=\"nofollow\" target=\"_blank\">www.ars-pharma.com<\/a>.<\/p>\n<p>\n        <strong>ARS Investor Contact:<\/strong><br \/>\n        <br \/>Monique Allaire, THRUST<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LR6-1gyswbduKuwds3Ptmf3uOMjtyh14xrWwlAkvbXZDI-NJ6LYJxoqwZ301cE7xhdumB28Eufl9bmgY-MSx-UVN7TwDOog4yzVpgbptveo=\" rel=\"nofollow\" target=\"_blank\">monique@thrustsc.com<\/a><\/p>\n<p>\n        <strong>ARS Media Contact:<\/strong><br \/>\n        <br \/>Christy Curran, Sam Brown Inc.<br \/>615.414.8668<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FqruoOkgBeqgvQmFIfaGOP5R5KzkbxOBZsi1eLQgLzKFRcGYWAO7mgV0K8Q8_woWMbj0dFyJbZE9znP2ViVyoD0121qIAPigNP_4VY6QBjkBeA8EjS97Lyh2Igf9CSG8\" rel=\"nofollow\" target=\"_blank\">christycurran@sambrown.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmYwNmMyZjktMjRkZi00ZWYwLTgzMjItNzM4NzJjMmNiNGVlLTEyMTY1MzAtMjAyNi0xMC0yOC1lbg==\/tiny\/ARS-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT \/ 4:30 p.m. ET to review its third quarter 2026 financial results. Dial-in information for conference participants may be obtained by\u00a0registering for the event. To access the webcast and slides, please visit the\u00a0Events &amp; Presentations\u00a0page in the Investors &amp; Media section of the Company\u2019s\u00a0website. A replay of the webcast will be available for 30 days following the event. About ARS Pharmaceuticals, Inc. ARS Pharma is a biopharmaceutical company &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ARS Pharma to Report Third Quarter 2026 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1014767","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ARS Pharma to Report Third Quarter 2026 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARS Pharma to Report Third Quarter 2026 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT \/ 4:30 p.m. ET to review its third quarter 2026 financial results. Dial-in information for conference participants may be obtained by\u00a0registering for the event. To access the webcast and slides, please visit the\u00a0Events &amp; Presentations\u00a0page in the Investors &amp; Media section of the Company\u2019s\u00a0website. A replay of the webcast will be available for 30 days following the event. About ARS Pharmaceuticals, Inc. ARS Pharma is a biopharmaceutical company &hellip; Continue reading &quot;ARS Pharma to Report Third Quarter 2026 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-28T20:07:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ARS Pharma to Report Third Quarter 2026 Financial Results\",\"datePublished\":\"2026-10-28T20:07:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/\"},\"wordCount\":259,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/\",\"name\":\"ARS Pharma to Report Third Quarter 2026 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc=\",\"datePublished\":\"2026-10-28T20:07:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharma-to-report-third-quarter-2026-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ARS Pharma to Report Third Quarter 2026 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ARS Pharma to Report Third Quarter 2026 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"ARS Pharma to Report Third Quarter 2026 Financial Results - Market Newsdesk","og_description":"SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) &#8212; ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT \/ 4:30 p.m. ET to review its third quarter 2026 financial results. Dial-in information for conference participants may be obtained by\u00a0registering for the event. To access the webcast and slides, please visit the\u00a0Events &amp; Presentations\u00a0page in the Investors &amp; Media section of the Company\u2019s\u00a0website. A replay of the webcast will be available for 30 days following the event. About ARS Pharmaceuticals, Inc. ARS Pharma is a biopharmaceutical company &hellip; Continue reading \"ARS Pharma to Report Third Quarter 2026 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-28T20:07:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ARS Pharma to Report Third Quarter 2026 Financial Results","datePublished":"2026-10-28T20:07:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/"},"wordCount":259,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/","name":"ARS Pharma to Report Third Quarter 2026 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc=","datePublished":"2026-10-28T20:07:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDM1NSM3OTE5NjE0IzIyMDQ5Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharma-to-report-third-quarter-2026-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ARS Pharma to Report Third Quarter 2026 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1014767"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014767\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1014767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1014767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1014767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}